MOGA and Novartis applaud 2021 recipient of the Cancer Achievement Award

Pharma News: The Medical Oncology Group of Australia (MOGA) and Novartis Oncology Cancer Achievement Award recognises outstanding contributions made by scientists, clinicians and other health professionals to cancer research and control in Australia.

Since 1999 this Award has been presented to 21 leaders in the field of Australian Oncology. 

In 2021 the Award will be presented at the Opening Ceremony for the Annual Scientific Meeting by this year’s recipient, Professor Clare Scott who will deliver the Award Address on Thursday 5 August.

“On behalf of Novartis Oncology, I would like to congratulate Professor Scott  for her remarkable achievements in research of ovarian and rare cancers, and improvement of patient outcomes. A very well-deserved award, representing considerable contributions towards the progress of medical care in this field,” said Dr Othon Gervasio, Medical Director, Novartis Group (Australia and New Zealand).

Professor Scott receives the Award for her meritorious contribution as a medical oncology clinician, clinician-researcher, leader and mentor. Clare Scott is Professor of Gynaecological Cancer Obstetrics and Gynaecology Royal Women’s Hospital/Mercy, University of Melbourne and Joint Division Head Division Clinical Translation, ACRF Cancer Biology and Stem Cells at The Walter and Eliza Hall Institute of Medical Research in Melbourne. Her dedication to rare and ovarian cancers research over the last decade has contributed significantly to the establishment of platforms whereby clinical, research and consumer organisations can collaborate to impact on rare cancer survivorship. Professor Scott’s skills in clinical oncology, evidence-based medicine and research have resulted in the leadership of numerous, influential clinical trials.